187 related articles for article (PubMed ID: 33888987)
1. Risk Factors for Tigecycline-Associated Hypofibrinogenemia.
Liu J; Yan Y; Zhang F
Ther Clin Risk Manag; 2021; 17():325-332. PubMed ID: 33888987
[TBL] [Abstract][Full Text] [Related]
2. Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: A multicenter retrospective study in China.
Leng B; Shen C; Gao T; Zhao K; Zhao X; Guo Y; Wu J; Yang J; Fang W; Zhang J; Zhang Y; Sun C; Duan L; Huang J; Qi Y; Yan G
Front Pharmacol; 2022; 13():943674. PubMed ID: 36304151
[No Abstract] [Full Text] [Related]
3. Tigecycline-associated hypofibrinogenemia in a real-world setting.
Campany-Herrero D; Larrosa-Garcia M; Lalueza-Broto P; Rivera-Sánchez L; Espinosa-Pereiro J; Mestre-Torres J; Pigrau-Serrallach C
Int J Clin Pharm; 2020 Aug; 42(4):1184-1189. PubMed ID: 32504166
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.
Zhang L; Cai X; Peng F; Tian S; Wu X; Li Y; Guo J
Front Pharmacol; 2023; 14():1182644. PubMed ID: 37351509
[No Abstract] [Full Text] [Related]
5. Risk factors of tigecycline-associated fibrinogen reduction in patients with renal transplantation: a case-control study.
Xie W; Ma K; Xu Z; Xie J; Lu X; Wang X
Transl Androl Urol; 2022 Oct; 11(10):1410-1418. PubMed ID: 36386261
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the clinical characteristics of tigecycline-induced hypofibrinogenemia.
Lei H; Liu X; Li Z; Wang C
J Chemother; 2023 Jul; 35(4):292-297. PubMed ID: 35904191
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study.
Firat O; Kara E; Malkan ÜY; Demirkan K; Inkaya AÇ
Thromb Res; 2024 Apr; 236():155-160. PubMed ID: 38452447
[TBL] [Abstract][Full Text] [Related]
8. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature.
Fan Q; Huang W; Weng Y; Xie X; Shi Z
Medicine (Baltimore); 2020 Oct; 99(43):e22638. PubMed ID: 33120753
[TBL] [Abstract][Full Text] [Related]
9. Safety of Tigecycline in Patients on Antithrombotic Therapy: A Single-Center Retrospective Study.
Lin C; Tan M; Wang D; Gu C; Wu Y; Wang S
Pharmacology; 2023; 108(6):540-549. PubMed ID: 37751720
[TBL] [Abstract][Full Text] [Related]
10. Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: A retrospective cohort study.
Yang X; Jin L; Luo X; Wang M; Zhu H; Zhou Y; Ge W
Int J Infect Dis; 2022 Oct; 123():136-142. PubMed ID: 36028209
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous Knee Hemarthrosis Due to Hypofibrinogenemia Following Tigecycline Treatment for Periprosthetic Joint Infection.
Balfousias T; Apostolopoulos AP; Angelis S; Maris S; Papanikolaou A
Cureus; 2019 Oct; 11(10):e5883. PubMed ID: 31772853
[TBL] [Abstract][Full Text] [Related]
12. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia.
Wu X; Zhao P; Dong L; Zhang X
Medicine (Baltimore); 2017 Dec; 96(49):e9124. PubMed ID: 29245350
[TBL] [Abstract][Full Text] [Related]
13. Tigecycline-associated hypofibrinogenemia: A case report and review of the literature.
Wu PC; Wu CC
IDCases; 2018; 11():56-57. PubMed ID: 29560313
[TBL] [Abstract][Full Text] [Related]
14. Acute pancreatitis caused by tigecycline and furosemide combination treatment and hypofibrinogenemia caused by tigecycline: A case report.
Li ZK; Zheng P
Int J Clin Pharmacol Ther; 2023 Oct; 61(10):466-470. PubMed ID: 37548456
[TBL] [Abstract][Full Text] [Related]
15. Progression of Fibrinogen Decrease during High Dose Tigecycline Therapy in Critically Ill Patients: A Retrospective Analysis.
Treml B; Rajsic S; Hell T; Fries D; Bachler M
J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682825
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Bleeding Risk Between Colistin-Tigecycline and Colistin-Carbapenem Treatment Regimens: A Retrospective Cohort Study.
Huang YT; Yu CI; Chen PY; Wang CC; Wu CC
Infect Drug Resist; 2021; 14():4949-4955. PubMed ID: 34858035
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for tigecycline-induced hypofibrinogenaemia.
Zhang Q; Wang J; Liu H; Ma W; Zhou S; Zhou J
J Clin Pharm Ther; 2020 Dec; 45(6):1434-1441. PubMed ID: 32860258
[TBL] [Abstract][Full Text] [Related]
18. Clinical Manifestations and Risk Factors of Tigecycline-Associated Thrombocytopenia.
Zhu Y; Zhao F; Jin P
Infect Drug Resist; 2023; 16():6225-6235. PubMed ID: 37732172
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of a Nomogram for Predicting Tigecycline-Related Coagulopathy: A Retrospective Cohort Study.
Li Z; Zeng Q; Xu S; Li Y; Tang T; Shi J; Song X; He W; Chen L; Liu G; Gao B; Zheng J; Huang L; Chen M; Jiang S
Infect Drug Resist; 2023; 16():423-434. PubMed ID: 36718461
[TBL] [Abstract][Full Text] [Related]
20. Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder.
Sabanis N; Paschou E; Gavriilaki E; Kalaitzoglou A; Vasileiou S
Infect Dis (Lond); 2015; 47(10):743-6. PubMed ID: 25951751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
